A Retrospective Study of Patients Undergoing Gastrointestinal Surgery with or without Receiving Alvimopan: Comparing Length of Stay and Total Direct Cost

Main Article Content

Yenisey Rodriguez Lister, Pharm.D,BCPS Raul Mederos, MD Nestor Veciana, Pharm.D


Objective: Alvimopan (Entereg®) has been shown to accelerate the recovery time of upper and lower gastrointestinal (GI) system following partial large or small bowel resection with primary anastomosis.

Alvimopan acquisition cost can increase health care costs. The purpose of this study is to assess the effectiveness of alvimopan reducing the length of stay (LOS) and total direct cost in patients undergoing gastrointestinal surgery.

Materials and methods: Data was collected using the Crimson Clinical Advantage software. The software identified 64 patients who underwent major small and large bowel surgical procedures from July 2018 to February 2019. Patients’ demographics, comorbidities, and treatment details were collected. Two groups where analyzed, patients that received alvimopan 12mg twice daily for up to 15 doses or until patients discharged, which ever occur first, with controls (patients who did not receive alvimopan). The data was retrospectively collected from patient records at Hialeah Hospital. The primary endpoints included reduction in both length of stay and total direct cost.

Results: The study reviewed 64 patients that met the inclusion criteria, 33 (51.5%) of these patients received alvimopan. When comparing both groups, alvimopan treatment was associated with a reduced duration mean of hospitalization (4.48 vs 7.39 days, P < 0.01). In addition, almivopan was also associated with a significant reduction of the average total direct cost for treatment group ($7,965 vs $9,100), a difference of 12.4%.

Conclusion: Patients who undergo segmental bowel resection with primary anastomosis and received alvimopan had a reduction of the length of stay and total direct costs compared with control group.

Article Details

How to Cite
RODRIGUEZ LISTER, Yenisey; MEDEROS, Raul; VECIANA, Nestor. A Retrospective Study of Patients Undergoing Gastrointestinal Surgery with or without Receiving Alvimopan: Comparing Length of Stay and Total Direct Cost. Medical Research Archives, [S.l.], v. 10, n. 7, july 2022. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/2590>. Date accessed: 02 oct. 2023. doi: https://doi.org/10.18103/mra.v10i7.2590.


1. Livingston EH, Passaro EP. Postoperative ileus. Dig Dis Sci. 1990;35:121-132.
2. Luckey A, Livingston EH, Taché Y. Mechanisms and treatment of postoperative ileus. Arch Surg. 2003;138:206-214.
3. Goodstein T, Launer B, White S. et al. A Retrospective Study of Patients Undergoing Radical Cystectomy and Receiving Peri-Operative Naloxegol or Alvimopan: Comparison of Length of Stay, Journal of Surgery. Vol. 6, No. 5, 2018, pp. 129-134. doi: 10.11648/j.js.20180605.14
4. Food and Drug Administration (FDA). Entereg label; 2008. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf. Accessed November 2, 2019.
5. Lee CT, Chang SS, Kamat AM, et al. Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial. Eur Urol. 2014;66(2):265-272. doi:10.1016/j.eururo.2014.02.036
6. Entereg (alvimopan) [prescribing information]. Whitehouse, Station, NJ: Merck Sharp & Dohme Corp; November 2020.
7. Alvimopan. Lexi-Comp Online®, Lexi-Drugs®, Hudson, Ohio: Lexi-Comp, Inc.; March 12, 2019.
8. Goldstein JL, Matuszewski KA, Delaney CP, et al. Inpatient economic burden of postoperative ileus associated with abdominal surgery in the United States. P&T 2007;32:82–90
9. Sultan S, Coles B, Dahm P. Alvimopan for recovery of bowel function after radical cystectomy. Cochrane Database of Systematic Reviews 2017, Issue 5. Art. No.: CD012111. DOI: 10.1002/14651858.CD012111.pub2
10. Herzog TJ, Coleman RL, Guerrieri JP Jr, et al. A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy. Am J Obstet Gynecol. 2006;195:445-453.
11. Wolff BG, Viscusi ER, Delaney CP, et al. Patterns of gastrointestinal recovery after bowel resection and total abdominal hysterectomy: pooled results from the placebo arms of alvimopan phase III North American clinical trials. J Am Coll Surg. 2007;205:43-45.
12. Delaney CP, Weese JL, Hyman NH, et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum. 2005;48:1114-1125.
13. Kraft M, Maclaren R, Du W, Owens G. Alvimopan (entereg) for the management of postoperative ileus in patients undergoing bowel resection. P T. 2010;35(1):44-49.
14. Poston S, Broder M.S, Bibbons M.M, et al. Impact of Alvimopan (Entereg) on Hospital Costs After Bowel Resection. P&T 2011; 36(4):209-220.
15. Bennedsen ALB, Eriksen JR, Gögenur I. Prolonged hospital stay and readmission rate in an enhanced recovery after surgery cohort undergoing colorectal cancer surgery. Colorectal Dis. 2018;20(12):1097-1108. doi:10.1111/codi.14446
16. Hernandez-Meza G, McKee S, Carlton D, Yang A, Govindaraj S, Iloreta A. Association of Surgical and Hospital Volume and Patient Characteristics With 30-Day Readmission Rates. JAMA Otolaryngol Head Neck Surg. 2019;145(4):328-337. doi:10.1001/jamaoto.2018.4504